Daniel Bradbury Sells 7,867 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) Director Daniel Bradbury sold 7,867 shares of the firm's stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total transaction of $221,613.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Daniel Bradbury also recently made the following trade(s):

• On Monday, January 6th, Daniel Bradbury sold 7,867 shares of Castle Biosciences stock. The shares were sold at an average price of $29.14, for a total transaction of $229,244.38.

Castle Biosciences Stock Up 1.5 %

Castle Biosciences stock traded up $0.41 during trading on Tuesday, hitting $28.12. 423,432 shares of the company were exchanged, compared to its average volume of 458,290. The business's 50 day moving average is $28.13 and its 200 day moving average is $29.03. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 52 week low of $16.97 and a 52 week high of $35.84. The company has a market capitalization of $787.64 million, a P/E ratio of 140.61 and a beta of 0.91.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CSTL. Point72 Asset Management L.P. lifted its position in shares of Castle Biosciences by 828.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 499,192 shares of the company's stock valued at $14,237,000 after buying an additional 445,415 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Castle Biosciences by 147.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 165,458 shares of the company's stock valued at $4,719,000 after buying an additional 98,571 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Castle Biosciences by 4.8% during the 4th quarter. Vanguard Group Inc. now owns 1,832,535 shares of the company's stock valued at $48,837,000 after buying an additional 83,783 shares during the last quarter. Hussman Strategic Advisors Inc. purchased a new position in shares of Castle Biosciences during the 4th quarter valued at $1,959,000. Finally, State Street Corp lifted its position in shares of Castle Biosciences by 9.8% during the 3rd quarter. State Street Corp now owns 680,001 shares of the company's stock valued at $19,394,000 after buying an additional 60,924 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CSTL. KeyCorp boosted their price target on shares of Castle Biosciences from $28.00 to $36.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. Lake Street Capital boosted their price target on shares of Castle Biosciences from $34.00 to $40.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. BTIG Research boosted their price target on shares of Castle Biosciences from $35.00 to $40.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Canaccord Genuity Group boosted their price target on shares of Castle Biosciences from $35.00 to $42.00 and gave the stock a "buy" rating in a research report on Tuesday, October 29th. Finally, Scotiabank boosted their price target on shares of Castle Biosciences from $37.00 to $44.00 and gave the stock a "sector outperform" rating in a research report on Wednesday, November 6th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $40.29.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.